A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis - PubMed
4 days ago
- #Triple-Negative Breast Cancer
- #Atezolizumab
- #Brain Metastases
- Phase II study evaluates atezolizumab combined with stereotactic radiosurgery (SRS) for triple-negative breast cancer (TNBC) patients with brain metastases.
- Primary endpoint was progression-free survival (PFS); secondary endpoints included extracranial response rate, overall survival (OS), and safety.
- No dose-limiting toxicities (DLTs) observed, but study closed early due to slow patient accrual.
- Median bi-compartmental PFS was 1.3 months, and median OS was 9.7 months.
- Concurrent SRS with atezolizumab was feasible, but disease outcomes remained poor, highlighting unmet medical needs.